NCR1 and neoplasm: In addition, some tumor cells also express ligands for NKp46, so it would be ideal if the NKp46 binder used in our bispecific engager did not block NKp46 from binding to its natural ligand on tumor cells, which may provide additional tumor ligand signals via NKp46.